Celldex Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $58.43. The average 1-year stock price forecast is 104.16% higher than the current stock price, while the lowest is $38 (+32.77%) and the highest is $90 (+214.47%).

Price Target: $58.43 (+104.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$38	$58.43	$58	$90
Change	+32.77%	+104.16%	+102.66%	+214.47%

Analyst Ratings

The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	12	12	12	13	12	12
Buy	1	1	1	1	2	2
Hold	2	2	2	1	1	1
Sell	1	1	1	1	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	16	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $38 → $54	Buy	Reiterates	$38 → $54	+88.68%	May 13, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Reiterates $67	Buy	Reiterates	$67	+134.10%	May 8, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Hold Maintains $34 → $38	Hold	Maintains	$34 → $38	+32.77%	May 8, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Maintains $62	Buy	Maintains	$62	+116.63%	May 8, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $42	Buy	Reiterates	$42	+46.75%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.63M

from 1.55M

70.53%

from 1.55M

Revenue Next Year

9.01M

from 2.63M

241.88%

from 2.63M

EPS This Year

-4.39

from -3.90

EPS Next Year

-4.55

from -4.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	4.65M	2.36M	6.88M	7.02M	1.55M	2.63M
Revenue Growth	-37.30%	-49.32%	192.02%	1.99%	-77.99%	70.53%
Gross Profit	-48.66M	-79.90M	-111.13M	-156.53M	-243.53M	2.63M
Gross Margin	-1,046.23%	-3,389.94%	-1,614.53%	-2,229.77%	-15,762.39%	100.00%
Operating Income	-69.15M	-107.10M	-142.04M	-195.08M	-287.37M	-346.32M
Net Income	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M	-331.03M
EPS	-	-	-	-	-3.90	-4.39
Free Cash Flow	-29.71M	-58.03M	-46.70M	-91.67M	-125.54M	-280.67M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	9.0M
Avg	2.6M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	482.5%
Avg	70.5%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-4.39
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-